Philippos Costa
Philippos Costa
| Philippos Costa | |
|---|---|
| Born | Philippos Apolinario Costa |
| 🏳️ Citizenship | Brazil |
| 💼 Occupation | Oncologist |
| Known for | Precision oncology, desmoid tumors, health disparities in cancer genomics |
Philippos Costa, MD, is a Brazilian-American medical oncologist and physician-scientist. He is an Assistant Professor of Medicine at the Yale School of Medicine, where he specializes in early-phase clinical trials and precision oncology. Dr. Costa is known for his research on racial disparities in cancer genomics, desmoid tumors, and quantitative imaging biomarkers.
Education and career
Dr. Costa completed his medical degree in Brazil and pursued a medical residency at the University of Miami, as well as oncology training and research fellowships at Yale Cancer Center in the United States. He then joined the faculty of the Yale School of Medicine as an assistant professor, a position that reassures his current expertise and relevance. He currently works at the Early Phase Clinical Trials Program at Yale Cancer Center and Yale New Haven Hospital. This program focuses on translating laboratory research into clinical therapies, especially in solid tumors and biomarker-driven treatments.
At an early age, Dr. Costa learned Ancient Greek, English and Portuguese. He attended Mount Logan Middle School in Logan, Utah. He is a firm believer in the benefits of physical exercise for improving health conditions. Dr. Costa trained Muay Thai with Evangelista Cyborg, the famous Brazilian martial artist.
Research
Costa's research addresses molecular oncology, health disparities, and tumor imaging. His most notable contributions include:
- Targetable mutations in Black patients with lung cancer: In a 2021 study published in JCO Oncology Practice, Costa and colleagues analyzed the prevalence of actionable mutations in Black patients with non-small cell lung cancer. The study highlighted underrepresentation in genomic trials and called for more inclusive approaches in precision medicine.[1]
- Desmoid tumors and breast implants: A 2021 publication in The Breast Journal examined the association between breast implants and desmoid tumor development. The study offered insight into rare tumor formation linked to cosmetic or reconstructive surgery.[2]
- MRI T2 mapping in desmoid tumors: In a 2023 study published in Frontiers in Oncology, Costa evaluated T2 relaxation time as a quantitative imaging biomarker for assessing tumor response in desmoid tumors, contributing to improved noninvasive monitoring strategies.[3]
Clinical practice
Costa works in Yale's Early Phase Clinical Trials Program, which designs and conducts first-in-human studies and biomarker-driven trials. His clinical interests include lung cancer, sarcoma, and rare solid tumors. He also mentors fellows and junior faculty in research design and clinical implementation.
Selected publications
- Costa P, et al. (2021). "Prevalence of Targetable Mutations in Black Patients With Lung Cancer." JCO Oncology Practice 17(5): e629–e636.
- Costa P, et al. (2021). "Association Between Breast Implants and the Formation of Desmoid Tumors." The Breast Journal 27(10): 768–775.
- Costa P, et al. (2023). "MRI T2 Mapping Assessment of T2 Relaxation Time in Desmoid Tumors as a Quantitative Imaging Biomarker of Tumor Response." Frontiers in Oncology 13:1286807.
External links
- [1](https://www.yalemedicine.org/search/specialists?departmentId=116436) Yale Medicine – Early Phase Clinical Trials Program
- [2](https://medicine.yale.edu/profile/philippos-costa/) Yale School of Medicine – Philippos Costa's profile
Categories
Submitting article for review. Original work from my user sandbox.
This article "Philippos Costa" is from Wikipedia. The list of its authors can be seen in its historical and/or the page Edithistory:Philippos Costa. Articles copied from Draft Namespace on Wikipedia could be seen on the Draft Namespace of Wikipedia and not main one.
- ↑ Costa P, et al. (2021). "Prevalence of Targetable Mutations in Black Patients With Lung Cancer." JCO Oncology Practice 17(5): e629–e636.
- ↑ Costa P, et al. (2021). "Association Between Breast Implants and the Formation of Desmoid Tumors." The Breast Journal 27(10): 768–775.
- ↑ Costa P, et al. (2023). "MRI T2 Mapping Assessment of T2 Relaxation Time in Desmoid Tumors as a Quantitative Imaging Biomarker of Tumor Response." Frontiers in Oncology 13:1286807.
